Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with ...

CURE® honored eight MPN Heroes, which ranged from medical professionals to patients and caregivers, on the contributions they ...

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma. Safety and efficacy ...

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor and hormone therapy combination in patients with advanced breast cancer were presented at SABCS. Treatment with bispecific ...

Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in ...

As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer ...

Because no matter how exhausted I was during my treatment, no matter how much I had to sleep things off, I couldn’t stagnate.

Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free ...

After being diagnosed with triple-negative breast cancer in November 2022. I went through five months of chemotherapy, ...

A new study aims to answer questions regarding end-of-life care for patients with stage 4 cancers and their caregivers.

A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete ...

Gear up: I still need to get outside. I don’t trust myself on icy paths or sidewalks because chemo-induced neuropathy means I ...